Chris van Weel

Chris van Weel

Auto-generated profile, based on publicly available information

Chris van Weel

Department of Primary and Community Care, Radboud University medical center, Nijmegen, the Netherlands

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2007 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
KRKlaus F. Rabe
Klaus F. Rabe
SHSuzanne Hurd
Suzanne Hurd
AAAntonio Anzueto
Antonio Anzueto
PBPeter Barnes
Peter Barnes
SBSonia A. Buist
Sonia A. Buist
JZJan Zielinski
Jan Zielinski
Chronic obstructive pulmonary disease (COPD) remains a major public health problem. It is the fourth leading cause of chronic morbidity and mortality in the United States, and is projected to rank fifth in 2020 in burden of disease worldwide, according to a study published by the World Bank/World Health Organization. Yet, COPD remains relatively unknown or ignored by the public as well as public health and government officials. In 1998, in an effort to bring more attention to COPD, its management, and its prevention, a committed group of scientists encouraged the U.S. National Heart, Lung, and Blood Institute and the World Health Organization to form the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Among the important objectives of GOLD are to increase awareness of COPD and to help the millions of people who suffer from this disease and die prematurely of it or its complications. The first step in the GOLD program was to prepare a consensus report, Global Strategy for the Diagnosis, Management, and Prevention of COPD, published in 2001. The present, newly revised document follows the same format as the original consensus report, but has been updated to reflect the many publications on COPD that have appeared. GOLD national leaders, a network of international experts, have initiated investigations of the causes and prevalence of COPD in their countries, and developed innovative approaches for the dissemination and implementation of COPD management guidelines. We appreciate the enormous amount of work the GOLD national leaders have done on behalf of their patients with COPD. Despite the achievements in the 5 years since the GOLD report was originally published, considerable additional work is ahead of us if we are to control this major public health problem. The GOLD initiative will continue to bring COPD to the attention of governments, public health officials, health care workers, and the general public, but a concerted effort by all involved in health care will be necessary.

7 March 2008 in Allergy
Verified
Journal Article
Open access
PDF file
JBJ. Bousquet
J. Bousquet
NKN. Khaltaev
N. Khaltaev
ACA. A. Cruz
A. A. Cruz
JDJ. Denburg
J. Denburg
WFW. J. Fokkens
W. J. Fokkens
DWD. Williams
D. Williams

26 July 2011 in BMJ
Verified
Journal Article
Closed access
PDF file
MHMachteld Huber
Machteld Huber
JKJ André Knottnerus
J André Knottnerus
LGLawrence Green
Lawrence Green
HHH. V. D. Horst
H. V. D. Horst
AJAlejandro R Jadad
Alejandro R Jadad
HSHenk Smid
Henk Smid
The WHO definition of health as complete wellbeing is no longer fit for purpose given the rise of chronic disease. Machteld Huber and colleagues propose changing the emphasis towards the ability to adapt and self manage in the face of social, physical, and emotional challenges

1 November 2010 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
PBPhilippe Jean Bousquet
Philippe Jean Bousquet
EMEva Mantzouranis
Eva Mantzouranis
ACAlvaro A. Cruz
Alvaro A. Cruz
NANadia Aït-Khaled
Nadia Aït-Khaled
CBCarlos E. Baena-Cagnani
Carlos E. Baena-Cagnani
TZTorsten Zuberbier
Torsten Zuberbier

1 January 2005 in Diabetes Care
Verified
Journal Article
Closed access
FLFloris A. van de Laar
Floris A. van de Laar
PLPeter L. Lucassen
Peter L. Lucassen
RAReinier P. Akkermans
Reinier P. Akkermans
ELEloy H. van de Lisdonk
Eloy H. van de Lisdonk
GRGuy E. Rutten
Guy E. Rutten
CWChris van Weel
Chris van Weel
OBJECTIVE—To review the effects of monotherapy with α-glucosidase inhibitors (AGIs) for patients with type 2 diabetes, with respect to mortality, morbidity, glycemic control, insulin levels, plasma lipids, body weight, and side effects.RESEARCH DESIGN AND METHODS—We systematically searched the Cochrane Central register of Controlled Trials, MEDLINE, EMBASE, Current Contents, LILACS, databases of ongoing trials, and reference lists, and we contacted experts and manufacturers. Inclusion criteria were randomized controlled trials of at least 12 weeks’ duration, AGI monotherapy compared with any intervention, and one of the following outcome measures: mortality, morbidity, GHb, blood glucose, lipids, insulin levels, body weight, or side effects. Two independent reviewers assessed all abstracts, extracted all data, and assessed quality. We contacted all authors for data clarification. Continuous data were expressed as weighted mean differences and analyzed with a random-effects model. Possible influences of study characteristics and quality were assessed in sensitivity and meta-regression analyses.RESULTS—Forty-one studies were included in the review (30 acarbose, 7 miglitol, 1 voglibose, and 3 combined), and heterogeneity was limited. We found no evidence for an effect on mortality or morbidity. Compared with placebo, AGIs had a beneficial effect on GHb (acarbose −0.77%; miglitol −0.68%), fasting and postload blood glucose and postload insulin. With acarbose dosages higher than 50 mg t.i.d., the effect on GHb was the same, but the occurrence of side effects increased. Acarbose decreased the BMI by 0.17 kg/m2 (95% CI 0.08–0.26). None of the AGIs had an effect on plasma lipids. Compared with sulfonylurea, AGIs seemed inferior with respect to glycemic control, but they reduced fasting and postload insulin levels. For comparisons with other agents, little data were available.CONCLUSIONS—We found no evidence for an effect on mortality or morbidity. AGIs have clear beneficial effects on glycemic control and postload insulin levels but not on plasma lipids. There is no need for dosages higher than 50 mg acarbose t.i.d.

1 November 2012 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
PBPhilippe Jean Bousquet
Philippe Jean Bousquet
HSH.J. Schünemann
H.J. Schünemann
BSB. Samolinski
B. Samolinski
PDPascal Demoly
Pascal Demoly
CBC.E. Baena-Cagnani
C.E. Baena-Cagnani
TZT. Zuberbier
T. Zuberbier